Drugs / Recombinant Fowlpox GM-CSF Vaccine Adjuvant
Recombinant Fowlpox GM-CSF Vaccine Adjuvant
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00072137 | Oct 2003 → Dec 2009 | bladder adenocarcinoma, bladder squamous cell carcinoma, urothelial carcinoma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 1 | NCT00028496 | Nov 2001 → Nov 2005 | adult hepatocellular carcinoma, cholangiocarcinoma, colon adenocarcinoma, diffuse gastric adenocarcinoma +11 | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant Fowlpox GM-CSF Vaccine Adjuvant | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00072137 ↗ |
| Modality | Vaccine | “recombinant fowlpox GM-CSF vaccine adjuvant” NCT00028496 ↗ |
| Route | Other | “Given intravesically” NCT00072137 ↗ |